Transcript : Skye Bioscience, Inc., Q1 2025 Earnings Call, May 08, 2025

Real-time Estimate Cboe BZX			5-day change	1st Jan Change
2.085 ^USD	-1.65%		-10.90%	-26.33%

Published on 06/17/2025 at 16:05

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, thank you for standing by. My name is Jay, and I will be your conference operator today. At this time, I would like to welcome

Unlock the article : SUBSCRIBE!

Skye Bioscience, Inc., Q1 2025 Earnings Call, May 08, 2025	04:05pm
Skye Bioscience, Inc. Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab	May. 19	CI
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	May. 13	RE
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral Cb1 Inhibition for Weight Loss Presented At European Congress on Obesity	May. 13	CI
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model	Apr. 15	RE
Skye Bioscience, Inc. Announces New Preclinical Data for its Novel CB1 Antibody, Nimacimab	Apr. 15	CI
Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update	Mar. 20	RE
Skye Bioscience, Inc., Q4 2024 Earnings Call, Mar 20, 2025	Mar. 20
Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Mar. 20	CI
Skye Bioscience, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-16-2025 10:30 AM	Jan. 16
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor	Nov. 14	CI
Skye Bioscience, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 12:30 PM	Nov. 13
Skye Bioscience, Inc., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model	Nov. 04	CI
Skye Bioscience Names Paul Grayson as Chairman of the Board	24-10-29	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index	24-09-23	CI
Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment	24-09-23	DJ
Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer	24-09-03	CI
Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity	24-08-22	CI
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-09	CI
Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints	24-07-24	CI
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab	24-07-11	CI
Skye Bioscience, Inc. Announces Board and Committee Changes, Effective August 1, 2024	24-07-03	CI

Duration

Period

EMBI: Dynamic Chart

Exclusive-US Health Secretary Kennedy to address Gavi vaccine event amid funding pullback

Tesla seeks to keep Texas robotaxi data under wraps, regulator says

Oil prices are now the stock market’s biggest driver

Tesla shares soar after first robotaxi rides hit the road in Austin, Texas

Fed’s Bowman open to cutting rates at July policy meeting

Fiserv shares rise on stablecoin launch plans

Top Premarket Decliners | MarketScreener

Commercial Metals misses Q3 revenue estimates

Amazon’s premium beauty push may be a buffer against Trump’s tariffs

Taker Buy Volume Spikes Sharply — TradingView News

Ethereum Price Crash To $2,100 Triggers Fear, But Why Are Analysts Predicting A Rally To $6,000? — TradingView News

Bitcoin Treasury Madness Signals The End Of The Current Rally

Ethereum (ETH) Consolidates Near $2400 As Bullish Pattern Signals 75% Rally

What Tariffs Will — and Won’t — Change for U.S. Bitcoin Miners

Ethereum Whale Activity Rises as ETH Price Gains 7%, What’s Next?

Exclusive-US Health Secretary Kennedy to address Gavi vaccine event amid funding pullback

Tesla seeks to keep Texas robotaxi data under wraps, regulator says

Oil prices are now the stock market’s biggest driver

Tesla shares soar after first robotaxi rides hit the road in Austin, Texas

Fed’s Bowman open to cutting rates at July policy meeting

Fiserv shares rise on stablecoin launch plans

Top Premarket Decliners | MarketScreener

Commercial Metals misses Q3 revenue estimates

Amazon’s premium beauty push may be a buffer against Trump’s tariffs

Taker Buy Volume Spikes Sharply — TradingView News

Ethereum Price Crash To $2,100 Triggers Fear, But Why Are Analysts Predicting A Rally To $6,000? — TradingView News

Bitcoin Treasury Madness Signals The End Of The Current Rally

Ethereum (ETH) Consolidates Near $2400 As Bullish Pattern Signals 75% Rally

What Tariffs Will — and Won’t — Change for U.S. Bitcoin Miners

Ethereum Whale Activity Rises as ETH Price Gains 7%, What’s Next?

Transcript : Skye Bioscience, Inc., Q1 2025 Earnings Call, May 08, 2025

Related Posts

Taker Buy Volume Spikes Sharply — TradingView News

Charitable giving grew to $593B in 2024, propelled by a strengthening US economy and a booming stock market

Ethereum Price Crash To $2,100 Triggers Fear, But Why Are Analysts Predicting A Rally To $6,000? — TradingView News

'The smoke is a lot worse than the fire'

Kraken's Ethereum Layer-2 Ink Network Is Launching a Token

BitMine Acquires 154 Bitcoin for $16.3M, Completes Treasury Build

Recent Posts

Navigate Site

Transcript : Skye Bioscience, Inc., Q1 2025 Earnings Call, May 08, 2025

Related Posts

Recent Posts

Navigate Site

Follow Us